TISSUEBLUE

Peak

brilliant blue g

NDAOPHTHALMICSOLUTIONPriority Review

Approved

Dec 2019

Lifecycle

Peak

Competitive Pressure

30/100

Data completeness

2/8 — Basic

Priority Review

TISSUEBLUE (brilliant blue g) is dyes [moa]. First approved in 2019.

Drug data last refreshed 4h ago · AI intelligence enriched 9h ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

TISSUEBLUE is an ophthalmic solution containing Brilliant Blue G, a dye-based disclosing agent approved in December 2019. It functions as a vital dye to enhance visualization of ocular tissues during ophthalmic surgical procedures. The product enables surgeons to better identify and differentiate anatomical structures in the eye.

LOE Approaching2mo to LOE

With only 0.2 years until LOE in December 2026, the brand team is in active defensive positioning; expect smaller, highly specialized teams focused on retention and procedure volume.

Mechanism of Action

Dyes

Pharmacologic Class:

Disclosing Agent

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Career Relevance

TISSUEBLUE represents a specialized, high-stakes career inflection point: the product is at peak lifecycle but facing imminent generic LOE in 0.2 years. Professionals joining this team should expect intense focus on volume retention, surgical customer relationships, and cost-containment strategies rather than growth trajectories.

Brand ManagerField Sales Representative

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.